These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1947353)

  • 21. Overview of tumor promotion in animals.
    Slaga TJ
    Environ Health Perspect; 1983 Apr; 50():3-14. PubMed ID: 6347683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic events during the process of cell transformation induced by carcinogens (review).
    Nguyen-Ba G; Vasseur P
    Oncol Rep; 1999; 6(4):925-32. PubMed ID: 10373683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens.
    Felter SP; Conolly RB; Bercu JP; Bolger PM; Boobis AR; Bos PM; Carthew P; Doerrer NG; Goodman JI; Harrouk WA; Kirkland DJ; Lau SS; Llewellyn GC; Preston RJ; Schoeny R; Schnatter AR; Tritscher A; van Velsen F; Williams GM
    Crit Rev Toxicol; 2011 Jul; 41(6):507-44. PubMed ID: 21591905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assay for initiators and promoters of carcinogenesis based on attachment-independent survival of cells in aggregates.
    Eker P; Sanner T
    Cancer Res; 1983 Jan; 43(1):320-3. PubMed ID: 6847775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multistage model of carcinogenesis incorporating DNA damage and repair.
    Portier CJ; Kopp-Schneider A
    Risk Anal; 1991 Sep; 11(3):535-43. PubMed ID: 1947359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multistage carcinogenesis in mouse skin.
    DiGiovanni J
    Pharmacol Ther; 1992; 54(1):63-128. PubMed ID: 1528955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioassays of shortened duration for drugs: statistical implications.
    Kodell RL; Lin KK; Thorn BT; Chen JJ
    Toxicol Sci; 2000 Jun; 55(2):415-32. PubMed ID: 10828275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinogenic mixtures.
    Krewski D; Thomas RD
    Risk Anal; 1992 Mar; 12(1):105-13. PubMed ID: 1574610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer.
    Lee PN
    Occup Environ Med; 2001 Mar; 58(3):145-53. PubMed ID: 11171926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A course of very small doses of DMBA, each of them allegedly with no promoting potency, acts with clear synergistic effect as a strong promoter of DMBA-initiated mouse skin carcinogenesis. A comparison of the tumorigenic and carcinogenic effects of DMBA (7,12-dimethylbenz-alpha-anthracene) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) used as initiators and promoters in classical two-stage experimental protocols.
    Iversen OH
    APMIS Suppl; 1994; 41():1-38. PubMed ID: 7946481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binary effects of carcinogens and tumor promoters--a preliminary chemical structural analysis of BCIDB and PCIDB.
    Rao VR
    J Toxicol Environ Health; 1991 Jun; 33(2):237-48. PubMed ID: 2051497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell culture systems for studying multifactor interactions in carcinogenesis.
    Weinstein IB
    Dev Toxicol Environ Sci; 1980; 8():149-64. PubMed ID: 6273101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nakahara Memorial Lecture. Pathways of carcinogenesis--genetic and epigenetic.
    Pitot HC; Dragan Y; Xu YH; Peterson J; Hully J; Campbell H
    Princess Takamatsu Symp; 1991; 22():21-33. PubMed ID: 1844243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell membrane associated protein kinase C as receptor of diterpene ester co-carcinogens of the tumor promoter type and the phenotypic expression of tumors.
    Hecker E
    Arzneimittelforschung; 1985; 35(12A):1890-903. PubMed ID: 3006705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation.
    Törnqvist M; Landin HH
    J Occup Environ Med; 1995 Sep; 37(9):1077-85. PubMed ID: 8528715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk assessment of peak exposure to genotoxic carcinogens: a pragmatic approach.
    Bos PM; Baars BJ; van Raaij MT
    Toxicol Lett; 2004 Jun; 151(1):43-50. PubMed ID: 15177639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-related differences in susceptibility to carcinogenesis. II. Approaches for application and uncertainty analyses for individual genetically acting carcinogens.
    Hattis D; Goble R; Chu M
    Environ Health Perspect; 2005 Apr; 113(4):509-16. PubMed ID: 15811844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-genotoxic factors in the carcinogenetic process: problems of detection and hazard evaluation.
    Parodi S; Malacarne D; Taningher M
    Toxicol Lett; 1992 Dec; 64-65 Spec No():621-30. PubMed ID: 1471216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Co-carcinogens of the initiation- (or tumor-) promoter type as cancer risk factors. A current problem of environmental carcinogenesis and experimental analysis of a typical etiologic model situation].
    Hecker E
    Naturwissenschaften; 1984 May; 71(5):259-61. PubMed ID: 6462252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.